Trial · NCT02498652
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cohort 1 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose) | Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1) |
| Primary | Cohort 1 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol. | Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose) | Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1) |
| Primary | Cohort 1 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%)) | Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose) | Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1) |
| Primary | Cohort 1 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%)) | Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose) | Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1) |
| Primary | Cohort 2 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose) | Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2) |
| Primary | Cohort 2 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol. | Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose) | Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2) |
| Primary | Cohort 2 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%)) | Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose) | Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2) |
| Primary | Cohort 2 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%)) | Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose) | Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2) |
| Secondary | Maximum Observed Concentration (Cmax) | Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose) | Cmax of Allopurinol alone or in combination with RDEA3170 |
| Secondary | Time of Occurrence of Maximum Observed Concentration (Tmax) | Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose) | Tmax of Allopurinol alone or in combination with RDEA3170 |
| Secondary | Area Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24) | Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose) | AUC 0-24 of Allopurinol alone or in combination with RDEA3170 |
| Secondary | Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Sampling Timepoint (AUC Last) | Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose) | AUC last of Allopurinol alone or in combination with RDEA3170 |
| Secondary | Apparent Terminal Half-life (t1/2) | Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose) | t1/2 of Allopurinol alone or in combination with RDEA3170 |
| Secondary | Number of Participants With Treatment-Emergent Adverse Events | 11 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02498652/registered